On May 15^th, 2025, the Phase I clinical trial for ZHB601 for Injection - a Class I new chemical drug independently developed by Zonhonbio with complete intellectual property rights both domestically and internationally - was officially initiated at Huashan Hospital affiliated to Fudan University.

As the sponsor, Zonhonbio has commenced this Phase I clinical study to evaluate "the safety, tolerability, and pharmacokinetic characteristics of ZHB601 for Injection in healthy volunteers."

Zonhonbio is dedicated to systematically developing humanized KKS system genetic engineering drugs, thoroughly exploring the potential applications and drug development possibilities of each component and their genetically engineered derivatives. Positioned as an innovator in central nervous system drugs, the company aims to provide more effective treatment options for patients with CNS disorders.